Sriwidodo Sriwidodo, Subroto Toto, Maksum Iman P, Wathoni Nasrul, Rostinawati Tina, Ulya Himmatul, Putri Indah U
Department of Pharmaceutic and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
J Pharm Bioallied Sci. 2019 Dec;11(Suppl 4):S562-S566. doi: 10.4103/jpbs.JPBS_207_19. Epub 2019 Dec 30.
Human Epidermal Growth Factor (hEGF) is a potential therapeutic protein that has been widely used as a healing agent for various chronic wounds. It induces the proliferation and metabolism of epithelial cells, regenerates skin cells, and validates skin elasticity. In the previous study, recombinant hEGF (rhEGF) had been successfully expressed extracellularly in Escherichia coli (E. coli) BL21 (DE3) using pectate lyase B (PelB) signal peptide. The previous study has shown that the medium concentration and the induction time influenced the production of rhEGF.
Therefore, this study was conducted to optimize the induction time and medium concentration for rhEGF extracellular secretion then followed by scale-up production.
This experiment was carried out using E. coli BL21 (DE3) which contains pD881 plasmid that carries hEGF and PelB gene. Optimization design of induction time and medium concentration were obtained using Central Composite Design (CCD).
The method of study started by the rejuvenation of E. coli culture, extracellular secretion, and optimization in the flask scale then followed by scaled-up production with high-cell density culture in the fermenter.
The optimization was carried out using Response Surface Methodology (RSM) and multi regression analysis.
This work showed that the multiplication of 1.5-fold medium concentration with induction time 3h after the culture started gave the best result among another condition in this study. Additionally, the rhEGF production in the fermenter scale was identified by SDS-PAGE Tricine and quantified by ELISA, which showed 122.40 μg of the rhEGF per milliliter medium.
In respect of the result, we conclude that the optimized condition of extracellular secretion was successfully obtained, and gives higher result before the previous study.
人表皮生长因子(hEGF)是一种潜在的治疗性蛋白质,已被广泛用作各种慢性伤口的愈合剂。它能诱导上皮细胞的增殖和代谢,再生皮肤细胞,并增强皮肤弹性。在先前的研究中,重组人表皮生长因子(rhEGF)已利用果胶酸裂解酶B(PelB)信号肽在大肠杆菌BL21(DE3)中成功进行细胞外表达。先前的研究表明,培养基浓度和诱导时间会影响rhEGF的产量。
因此,本研究旨在优化rhEGF细胞外分泌的诱导时间和培养基浓度,然后进行放大生产。
本实验使用含有携带hEGF和PelB基因的pD881质粒的大肠杆菌BL21(DE3)进行。采用中心复合设计(CCD)获得诱导时间和培养基浓度的优化设计。
研究方法始于大肠杆菌培养物的复苏、细胞外分泌以及摇瓶规模的优化,然后在发酵罐中进行高细胞密度培养的放大生产。
使用响应面法(RSM)和多元回归分析进行优化。
本研究表明,在培养开始后3小时诱导,培养基浓度增加1.5倍,在本研究的其他条件中产生了最佳结果。此外,通过SDS-PAGE Tricine鉴定发酵罐规模中的rhEGF产量,并通过ELISA进行定量,结果显示每毫升培养基中有122.40μg rhEGF。
基于结果,我们得出结论,成功获得了细胞外分泌的优化条件,并且比先前的研究有更高的产量。